Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Tang, Eve ^a   Ravaud, Philippe ^a,b,c,d   Riveros, Carolina ^b   Perrodeau, Elodie ^b   Dechartres, Agnes ^b,c,d  

^a Columbia University Mailman School of Public Health ^*  (United States)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Hôpital Hôtel Dieu Centre d'Epidémiologie Clinique Assistance Publique Hôpitaux de Paris ^*  (France)

Author keywords

Randomized controlled trials; Registration; Reporting; Safety; Serious adverse events; Transparency

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTENT ANALYSIS; CONTROLLED STUDY; DISEASE ONTOLOGY; INFORMATION PROCESSING; MEDICAL LITERATURE; PUBLICATION; ACCESS TO INFORMATION; ADVERSE DRUG REACTION; DRUG SURVEILLANCE PROGRAM; HUMAN; METHODOLOGY; PROCEDURES; PUBLISHING; SEVERITY OF ILLNESS INDEX; STANDARDS; STATISTICS AND NUMERICAL DATA;

ACCESS TO INFORMATION; ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PUBLICATIONS; PUBLISHING; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 84939137994     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0430-4     Document Type: Article

References (34)

1. Antes G, Chalmers I. Under-reporting of clinical trials is unethical. Lancet. 2003;361:978-9.
2. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Obstet Gynecol. 2009;114:1341-5.
3. Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990;263:1405-8.
4. Ioannidis JA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437-43.
5. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169:1756-61.
6. ClinicalTrials.gov "Basic Results" Data Element Definitions. 2013; http://prsinfo.clinicaltrials.gov/results_definitions.html#AdverseEventsDefinition. Accessed March 2015.
7. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781-8.
8. Ioannidis JPA, Contopoulos-Ioannidis DG. Reporting of safety data from randomised trials. Lancet. 1998;352:1752-3.
9. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol. 2006;24:3933-8.
10. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis", N Engl J Med 2000;343:1520-8. N Engl J Med. 2005;353:2813-4.
11. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med. 2006;354:1193.
12. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? BMJ. 2007;334:120-3.
13. Dickersin K, Rennie D. The evolution of trial registries and their use to assess the clinical trial enterprise. JAMA. 2012;307:1861-4.
14. Tse T, Williams RJ, Zarin DA. Reporting "basic results" in ClinicalTrials.gov. Chest. 2009;136:295-303.
15. Tse T, Williams RJ, Zarin DA. Update on registration of clinical trials in ClinicalTrials.gov. Chest. 2009;136:304-5.
16. Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med. 2013;10:e1001566.
17. The R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014.
18. Hartung DM, Zarin DA, Guise JM, McDonagh M, Paynter R, Helfand M. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med. 2014;160:477-83.
19. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ. 2014;349:g6501.
20. Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ. 2014;348:f7668.
21. Peron J, Maillet D, Gan HK, Chen EX, You B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol. 2013;31:3957-63.
22. Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014;32:83-9.
23. Hodkinson A, Kirkham JJ, Tudur-Smith C, Gamble C. Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open. 2013;3, e003436.
24. Smith SM, Chang RD, Pereira A, Shah N, Gilron I, Katz NP, et al. Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review. Pain. 2012;153:2415-21.
25. Becker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of results in ClinicalTrials.gov and high-impact journals. JAMA. 2014;311:1063-5.
26. Becker JE, Ross JS. Reporting discrepancies between the clinicaltrials.gov results database and peer-reviewed publications. Ann Intern Med. 2014;161:760.
27. Europe votes for clinical trial transparency. http://www.alltrials.net/news/europe-votes-for-clinical-trial-transparency. Accessed March 2015.
28. Posting of clinical trial summary results in European Clinical Trials Database (EudraCT) to become mandatory for sponsors as of 21 July 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/06/news_detail_002127.jsp&mid=WC0b01ac058004d5c1. Accessed March 2015.
29. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med. 2015;372:1031-9.
30. Gill CJ. How often do US-based human subjects research studies register on time, and how often do they post their results? A statistical analysis of the Clinicaltrials.gov database. BMJ Open. 2012;2. doi: 10.1136/bmjopen-2012-001186.
31. Nguyen TA, Dechartres A, Belgherbi S, Ravaud P. Public availability of results of trials assessing cancer drugs in the United States. J Clin Oncol. 2013;31:2998-3003.
32. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ. 2012;344:d7373.
33. Saito H, Gill CJ. How frequently do the results from completed US clinical trials enter the public domain? A statistical analysis of the ClinicalTrials.gov database. PLoS One. 2014;9, e101826.
34. Maruani A, Boutron I, Baron G, Ravaud P. Impact of sending email reminders of the legal requirement for posting results on ClinicalTrials.gov: cohort embedded pragmatic randomized controlled trial. BMJ. 2014;349:g5579.